Open access · OA
via OpenAlex
TARGETING AGING WITH METFORMIN (TAME)
Innovation in Aging · 2017 · ▲ 30 citations
Abstract
Metformin is one drug that targets the biology of aging and extends life- and health-span in animals. It is used for the treatment of and to delay type 2 diabetes mellitus (T2DM), with an over 60 years outstanding safety record. Metformin use is also associated with lower rates of cancer, CVD, all-cause mortality and possibly less cognitive decline. We designed TAME, a placebo controlled, multi-center study in ~3000 elderly aged 65–79, with a novel primary outcome of delaying the incidence of a composite of multiple age-related diseases. Additional outcomes relate to geriatric syndromes and functional health. The study was developed in consultation with the FDA to obtain a new FDA indication to target aging. This indication would allow industry to justify the development of next-generation drugs to target aging and will further extend healthy life span in the next decade, utilizing the experimental template provided by TAME.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/geroni/igx004.2682
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Barzilai, N. (2017). TARGETING AGING WITH METFORMIN (TAME). <em>Innovation in Aging</em>. https://doi.org/10.1093/geroni/igx004.2682
Vancouver
Barzilai N. TARGETING AGING WITH METFORMIN (TAME). Innovation in Aging. 2017. doi:10.1093/geroni/igx004.2682.
BibTeX
@article{nir2017TARGET,
title = {TARGETING AGING WITH METFORMIN (TAME)},
author = {Nir Barzilai},
journal = {Innovation in Aging},
year = {2017},
doi = {10.1093/geroni/igx004.2682},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging 2013
Open access · CC-BY
Rapamycin extends life- and health span because it slows aging
Dana-Farber Cancer Institute 2022
Open access · US-GOV
Resilience and Equity in Aging, Cancer, and Health (REACH): Promoting Physical Resilience and Cancer Care Equity for Adults Age 65 and Older Diagnosed With Gastrointestinal Malignancy
GeroScience 2022
Open access · OA
Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment
Sinovac Life Sciences Co., Ltd. 2020
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above
AGE 2005
Open access · OA
Genetic approaches to study aging in Drosophila melanogaster
Shenzhen Kangtai Biological Products Co., LTD 2021
Open access · US-GOV